The US Food and Drug Administration (FDA) is leaning toward authorizing half-dose booster injections of Moderna Inc’s COVID-19 vaccine, Bloomberg News reported Tuesday, citing people familiar with the matter.
The FDA had been seeking information on the effectiveness of a full third dose of Moderna vaccine, but is now ready to go ahead and consider Moderna’s proposed half-dose booster, according to the report.
Moderna and the FDA did not immediately respond to Reuters’ request for comment outside of normal business hours.
Moderna submitted her application to the US Food and Drug Administration on September 1 seeking authorization for a booster shot.
The original Moderna vaccine contains 100 micrograms of mRNA in each injection. The company’s submission to regulators to authorize a half-dose booster would allow Moderna to produce more.